Myriad Genetics, Inc. company was founded in 1991 and is headquartered in Salt Lake City, Utah. Myriad Genetics, Inc., a healthcare company, focuses on the development and marketing of novel molecular diagnostic products. It commercializes predictive medicine, personalized medicine, and prognostic medicine products. The company markets BRACAnalys for assessing a woman's risk for breast and ovarian cancer; COLARIS molecular for assessing a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP, a molecular diagnostic product for colon cancer that detects mutations in the APC and MYH genes; and MELARIS, which assesses a persons risk of developing melanoma. It also offers OnDose, a personalized medicine product to measure a patient's exposure to 5-FU chemotherapy; PREZEON that assesses loss of PTEN function in cancer patients; and TheraGuide 5-FU assesses a person's risk of developing a toxic reaction to 5-FU-based chemotherapy.

Nutraceutical International Corp. was founded in 1993 and is based in Park City, Utah. Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third parties; and owns neighborhood natural food markets and health food stores. Nutraceutical International sells its products primarily to and through domestic health and natural food stores.

Cortex Pharmaceuticals develops drugs to treat neurodegenerative and psychiatric disorders. Its research focuses on the AMPA receptor, which facilitates communication between nerve cells; the firm's Ampakine compounds may enhance this receptor's activity. Its lead drug candidate is CX717, which it is developing for a number of indications including respiratory depression (a potentially fatal side effect of some anesthetics and post-surgical painkillers), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and daytime sleepiness. The firm believes Ampakine drugs may also be helpful in treating a variety of other brain-related disorders, including depression, autism, and Huntington's disease.

United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular and infectious diseases, and cancer in the United States and Internationally. United's products include Remodulin (treprostinil sodium) for the treatment of pulmonary arterial hypertension; and CardioPAL SAVI and Decipher Cardiac Monitors for the treatment of cardiac arrhythmias and ischemic heart disease. Its NDA filed products include Inhaled Treprostinil for pulmonary arterial hypertension and Oral Tadalafil for pulmonary hypertension. United's Phase III products comprise of Oral Treprostinil for pulmonary arterial hypertension; and Phase II products include Beraprost-MR for pulmonary arterial hypertension, 3F8 MAb for neuroblastoma, Oral Treprostinil for Peripheral vascular disease, and CardioPAL SAVI Wireless Cardiac Event Monitors for Cardiac arrhythmias and ischemic heart disease. Its Phase I products include Inhaled Treprostinil for pulmonary arterial hypertension associated with Idiopathic pulmonary fibrosis, Inhaled Treprostinil with AERx Essence for Pulmonary hypertension, 8H9 MAb for Metastatic brain cancer, and Celgosivir for Hepatitis C. United's pre-clinical products comprise Miglustat for Hepatitis C and Glycobiology Antiviral Agents for Hepatitis C and other infectious diseases.

AVI BioPharma, Inc. was founded in 1980 and is based in Corvallis, Oregon. AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company's products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley's Fund, Inc.; and the United States Department of Defense.

InSite Vision Incorporated company was founded in 1986 and is based in Alameda, California. InSite Vision Incorporated operates as an ophthalmic product development company in the United States. It engages in the development and commercialization of ophthalmic pharmaceutical products based on DuraSite drug delivery technology. The company offers AzaSite for the treatment of bacterial conjunctivitis. It develops ISV-502, which completed Phase III (a) clinical trial for the treatment of blepharoconjunctivitis, an infection of the eyelid and the conjunctiva, as well as other ophthalmic infections; and ISV-405, a preclinical development candidate for the treatment of ocular infection. InSite Vision Incorporated has collaborative, licensing, and service agreements with Shin Poong Pharm Co., Ltd.; Bioceutica S.A.; Biem Pharmaceuticals; Essex Bio-Technology; Pfizer Inc. and Pfizer Products, Inc.; and Inspire Pharmaceuticals, Inc.; Catalent Pharma Solutions; and Bausch and Lomb Incorporated.

Hybrigenics wants to open a new pathway towards the fight against cancer. Established in 1997, the drug discovery company zeroes in on new drug targets and therapeutic biological components with the help of its computer programs involving protein sequencing and other high tech chemical screening techniques. What separates it from other drug researching companies is its Laboratory Information Management System (LIMS), a product that commercializes its library screening and navigating capabilities regarding DNA and other related biological sequencing. With its headquarters in Paris, Hybrigenics also owns Semaia BV, a subsidiary located in the Netherlands, and an additional office in the US.

Nabi Biopharmaceuticals company was founded in 1967 and is headquartered in Rockville, Maryland. Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland.

Emisphere Technologies, Inc. company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its ‘eligen’ technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the company’s product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc.

Nile Therapeutics, Inc. company was founded in 2005 and is based in San Mateo, California. Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.